Precise clinical study preliminary results favorable for intuitive's ion endoluminal system for peripheral nodule lung biopsy

Sunnyvale, calif., oct. 18, 2021 (globe newswire) -- intuitive (nasdaq: isrg), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the release of preliminary data from 69 subjects participating in the prospective, multi-center evaluation of the clinical utility (precise) – a post-market, multi-center clinical trial of its ion endoluminal system.
ISRG Ratings Summary
ISRG Quant Ranking